VivoSeq
Oncology

Chronic Lymphocytic Leukemia (CLL)

4

Pipeline Programs↗

9

Active Trials↗

4

Companies Involved↗

Chronic Lymphocytic Leukemia (CLL) is an early-stage landscape with 4 programs across 4 companies. The most active players are Nurix Therapeutics, Inc., AstraZeneca, AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nurix Therapeutics, Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

NX-5948

Nurix Therapeutics, Inc.

ACALABRUTINIB

AstraZeneca

Venetoclax

AbbVie

Obinutuzumab

Roche

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

9

clinical trials

Recruiting6 · 67%
Active, not recruiting2 · 22%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Recruiting·IiOMEDICO AG·N/A·NCT06043011·2,950 enrolled
Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
Recruiting·AbbVie logoAbbVie·N/A·NCT03342144·500 enrolled
The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07024706·80 enrolled
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT05724121·135 enrolled
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting·NNurix Therapeutics, Inc.·Phase 1·NCT05131022·572 enrolled
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
Recruiting·NNurix Therapeutics, Inc.·Phase 2·NCT07221500·100 enrolled
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04419519·81 enrolled
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04447768·100 enrolled
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors
Not yet recruiting·Centre Hospitalier de la côte Basque·Preclinical·NCT07592481·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)